Standard Biotools (LAB) Accounts Payables (2010 - 2026)

Standard Biotools (LAB) has 17 years of Accounts Payables data on file, last reported at $8.0 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 32.02% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 32.02% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, up 7.09% from the prior year.
• Accounts Payables for Q1 2026 stood at $8.0 million, up from $5.4 million in the prior quarter.
• Over the last five years, Accounts Payables for LAB reached as high as $13.1 million in Q1 2024 and fell as low as $5.0 million in Q4 2024.
• Historically, Accounts Payables has averaged $8.7 million across 5 years, with a median of $8.0 million in 2026.
• Across the five-year window, Accounts Payables plunged 51.19% in 2023 and surged 115.11% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $7.9 million in 2022, then advanced by 16.7% to $9.2 million in 2023, then plunged by 45.33% to $5.0 million in 2024, then gained by 7.09% to $5.4 million in 2025, then soared by 48.09% to $8.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $8.0 million in Q1 2026, $5.4 million in Q4 2025, and $6.6 million in Q3 2025.